NEW YORK, Feb 22 - Bayer and Curagen received clearance from the Federal Trade Commission Thursday to complete a $124 million functional genomics deal and a $1.34 billion deal to jointly develop obesity drugs.

The proposed deal did not violate the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the FTC said. Following the approval, Bayer completed the purchase of $85 million in Curagen common stock.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.